ZFIN ID: ZDB-FISH-150901-3654
Fish name: y1Tg
Genotype: y1Tg
Targeting Reagent: none
HUMAN DISEASE MODELED by y1Tg
Human Disease Conditions Citations
atherosclerosis chemical treatment by injection: agarose, physical alteration: intersegmental vessel Choi et al., 2017
breast cancer cancer xenotransplantation Jia et al., 2016
cancer xenotransplantation Hung et al., 2016
cancer cancer xenotransplantation Wang et al., 2016
cancer xenotransplantation Yang et al., 2015
cancer xenotransplantation Mercatali et al., 2016
cancer xenotransplantation Li et al., 2016
cancer xenotransplantation Stantic et al., 2015
cancer xenotransplantation Itou et al., 2017
cancer xenotransplantation Liu et al., 2017
cancer xenotransplantation Gnosa et al., 2016
cancer xenotransplantation Hsieh et al., 2017
cancer xenotransplantation Huang et al., 2017
cancer xenotransplantation Weijts et al., 2017
cancer xenotransplantation Vazquez Rodriguez et al., 2017
cancer xenotransplantation Würth et al., 2017
cancer xenotransplantation CichoD et al., 2014
cancer xenotransplantation Fu et al., 2016
cancer xenotransplantation Wu et al., 2017
cancer xenotransplantation Baltrunaite et al., 2017
cancer xenotransplantation Yang et al., 2016
cancer xenotransplantation Fior et al., 2017
cancer xenotransplantation Aveic et al., 2017
hepatocellular carcinoma cancer xenotransplantation Tonon et al., 2016
insulinoma cancer xenotransplantation Buishand et al., 2016
melanoma cancer xenotransplantation Evensen et al., 2016
neuroendocrine tumor cancer xenotransplantation Gaudenzi et al., 2017
oral squamous cell carcinoma cancer xenotransplantation Xiong et al., 2013
prostate cancer cancer xenotransplantation Zoni et al., 2017
pulmonary hypertension chemical treatment by environment: sodium nitroprusside Sasagawa et al., 2016
retinoblastoma cancer xenotransplantation Chen et al., 2015
retinopathy of prematurity chemical treatment: cobalt dichloride Wu et al., 2015
chemical treatment: GS4012 Wu et al., 2015
squamous cell carcinoma cancer xenotransplantation Martins et al., 2015
GENE EXPRESSION
Gene expression in y1Tg
RNA expression
Expressed Gene Structure Conditions Figures
amot standard conditions Fig. 6 from Zheng et al., 2009
amotl1 standard conditions Fig. 6 from Zheng et al., 2009
apela control Fig. 3 with image from Helker et al., 2015
apln amputation: fin, chemical treatment: cobalt dichloride, hypoxia Fig. 5 from Eyries et al., 2008
aplnra amputation: fin, chemical treatment: cobalt dichloride, hypoxia Fig. 5 from Eyries et al., 2008
aplnrb amputation: fin, chemical treatment: cobalt dichloride, hypoxia Fig. 5 from Eyries et al., 2008
bmp2b standard conditions Fig. 7 with image from Swartz et al., 2011
bmp4 standard conditions Fig. 7 with image from Swartz et al., 2011
brpf1 standard conditions Fig. 3 with image from Laue et al., 2008
cdh5 standard conditions Fig. S1 from Sauteur et al., 2014
Fig. 6 from Cermenati et al., 2013
Fig. 8 from Hayashi et al., 2013
Fig. 1 with image from Herwig et al., 2011
Fig. 7 with imageFig. 8 with image from Wang et al., 2010
Fig. 6 from Zheng et al., 2009
Fig. 3 with imageFig. 4 with image from Blum et al., 2008
col22a1 standard conditions Fig. 3 with image from Huang et al., 2009
ctsk control Fig. 5 with image from Petrey et al., 2012
cttnl standard conditions Fig. S7 from Kaluza et al., 2011
cyp1a chemical treatment: pharmaceutical Fig. 2Fig. 3 from Incardona et al., 2011
dab2 control Fig. 6 from Cermenati et al., 2013
Fig. 8 from Zou et al., 2011
dlc standard conditions Fig. S8 from Kobayashi et al., 2014
dld standard conditions Fig. S8 from Kobayashi et al., 2014
dock1 standard conditions Fig. 2 from Epting et al., 2010
efnb2a control Fig. 1 from Aranguren et al., 2011
egfl7 control Fig. 8 from Zou et al., 2011
egr1 physical alteration: anatomical structure Fig. 7 with imageFig. 8 with image from Huang et al., 2008
epas1b standard conditions Fig. 3 with image from Rojas et al., 2007
ephb2a control Fig. S9 from Cvejic et al., 2011
ephb4a control Fig. 1 from Aranguren et al., 2011
etv2 control Fig. 3 from Baltrunaite et al., 2017
cancer xenotransplantation Fig. 3 from Baltrunaite et al., 2017
fgf10a standard conditions Fig. 7 with image from Swartz et al., 2011
fgfr1a control Fig. 1 with image from De Smet et al., 2014
fgfr2 control Fig. 1 with image from De Smet et al., 2014
fgfr3 control Fig. 1 with image from De Smet et al., 2014
fgfr4 control Fig. 1 with image from De Smet et al., 2014
fli1a standard conditions Fig. 5 with image from Eve et al., 2017
Fig. S5 with image from Wakayama et al., 2015
Fig. 4 with image from Oehlers et al., 2011
Fig. 6 from Cermenati et al., 2008
Fig. 6Fig. 7 from Cirone et al., 2008
Fig. 6 from Potente et al., 2007
chemical treatment: O-(chloroacetylcarbamoyl)fumagillol Fig. 4 with image from Oehlers et al., 2011
Fig. 7 from Cirone et al., 2008
fli1b control Fig. 3 from Baltrunaite et al., 2017
cancer xenotransplantation Fig. 3 from Baltrunaite et al., 2017
flt4 control Fig. 6 from Cermenati et al., 2013
Fig. 1 from Aranguren et al., 2011
fmnl1b standard conditions Fig. S5 with image from Wakayama et al., 2015
fmnl2a standard conditions Fig. S5 with image from Wakayama et al., 2015
fmnl2b standard conditions Fig. S5 with image from Wakayama et al., 2015
fmnl3 standard conditions Fig. S5 with image from Wakayama et al., 2015
gata1a standard conditions Fig. 5 with image from Eve et al., 2017
Fig. 2 from Hart et al., 2007
gipc1 standard conditions Fig. S1 from Chittenden et al., 2006
Fig. 4 from Wang et al., 2006
gnat2 control Fig. 2 from Alvarez et al., 2010
chemical treatment: glucose Fig. 2 from Alvarez et al., 2010
gpr183a control Fig. S3 with image from Zhang et al., 2015
hbae1.1 control Fig. 2 with image from Jin et al., 2009
hbbe1.1 standard conditions Fig. 5 with image from Eve et al., 2017
hey2 control Fig. 1 from Aranguren et al., 2011
hif1ab standard conditions Fig. 2 with image from Rojas et al., 2007
hmgb1a control Fig. 4 from Fang et al., 2014
physical alteration: spinal cord Fig. 4 from Fang et al., 2014
hsd3b standard conditions Fig. 2 with imageFig. 6 with imageFig. 7 with image from Liu et al., 2006
igfbp7 standard conditions Fig. 4 from Hooper et al., 2009
isl2a standard conditions Fig. S1 from Chittenden et al., 2006
jam2a standard conditions Fig. 3 from Kobayashi et al., 2014
junba standard conditions Fig. 2 with image from Kiesow et al., 2015
junbb standard conditions Fig. 2 with image from Kiesow et al., 2015
kdrl standard conditions Fig. 3 from Baltrunaite et al., 2017
Fig. 2 with image from Kiesow et al., 2015
Fig. 8 from Zou et al., 2011
chemical treatment: vascular endothelial growth factor receptor antagonist Fig. 4 with image from Monteiro et al., 2016
cancer xenotransplantation Fig. 3 from Baltrunaite et al., 2017
klf2a control Fig. 4 from Jiménez-Amilburu et al., 2015
lcp1 control Fig. 4 with image from Jin et al., 2009
lhx6 standard conditions Fig. 5 with image from Swartz et al., 2011
lmo2 resection: caudal fin Fig. 5 from Meng et al., 2016
lyve1b control Fig. 6 from Cermenati et al., 2013
mcamb control Fig. 4 from Liu et al., 2016
transection: spinal cord Fig. 4 from Liu et al., 2016
meox1 standard conditions Fig. 2 from Nguyen et al., 2014
mir30a standard conditions Fig. S1 from Jiang et al., 2013
mir30b standard conditions Fig. S1 from Jiang et al., 2013
mir30c standard conditions Fig. S1 from Jiang et al., 2013
mir30d standard conditions Fig. S1 from Jiang et al., 2013
mir30e-2 standard conditions Fig. S1 from Jiang et al., 2013
mir126a standard conditions Fig. 4 from Zou et al., 2011
mir126b standard conditions Fig. 4 from Zou et al., 2011
mlc1 standard conditions Fig. 4 from Sirisi et al., 2014
msx1a standard conditions Fig. 5 with image from Swartz et al., 2011
myb standard conditions Fig. 1Fig. 3Fig. 6 from Jin et al., 2007
myod1 standard conditions Fig. 5 with image from Eve et al., 2017
ncor2 standard conditions Fig. 1 from Wei et al., 2014
nostrin control Fig. 1 from Kovacevic et al., 2012
notch3 standard conditions Fig. 2 with image from Wang et al., 2014
npas4a standard conditions Fig. 7 from Esser et al., 2017
ntn1a control Fig. 3text only from Wilson et al., 2006
ntn4 control Fig. 1Fig. S1 from Lambert et al., 2012
osr1 standard conditions Fig. 5 with image from Swartz et al., 2011
osr2 standard conditions Fig. 5 with image from Swartz et al., 2011
pak1 control Fig. 8 from Zou et al., 2011
pax2a control Fig. 2 from Hart et al., 2007
pax9 standard conditions Fig. 5 with image from Swartz et al., 2011
pcna standard conditions Fig. 2 from Leung et al., 2005
pdgfrb standard conditions Fig. 5 with image from McCarthy et al., 2016
Fig. 2 with image from Kok et al., 2015
Fig. 1 with imageFig. 2 with imageFig. 4 with imageFig. 6 with imageFig. S1 with image from Wang et al., 2014
phkg1a standard conditions Fig. S8 from Camus et al., 2012
podxl2 standard conditions Fig. 6 with image from Sauteur et al., 2017
Fig. 8 from Hayashi et al., 2013
prox1a control Fig. 2 from Aranguren et al., 2011
prp standard conditions Fig. 3 with image from Huang et al., 2009
ptger3 standard conditions Fig. 1 from Chen et al., 2017
pth1ra standard conditions Fig. 1 from Gray et al., 2013
rag1 standard conditions Fig. S7 from Cvejic et al., 2011
Fig. 1Fig. 2Fig. 5 from Jin et al., 2007
reck standard conditions Fig. 5 with image from Ulrich et al., 2016
robo4 standard conditions Fig. S1 from Chittenden et al., 2006
runx1 standard conditions Fig. 5 with image from Eve et al., 2017
s1pr1 standard conditions Fig. 2 from Mendelson et al., 2013
Fig. 4 with image from Ben Shoham et al., 2012
s1pr2 standard conditions Fig. 2 from Mendelson et al., 2013
s1pr3a standard conditions Fig. 2 from Mendelson et al., 2013
shha standard conditions Fig. 7 with image from Swartz et al., 2011
sirt1 standard conditions Fig. 4 from Potente et al., 2007
spi1b standard conditions Fig. 5 with image from Eve et al., 2017
syt2a standard conditions Fig. 2 with image from Kiesow et al., 2015
tal1 standard conditions Fig. 5 with image from Eve et al., 2017
tcf7l2 standard conditions Fig. 2 with image from Facchinello et al., 2017
tek resection: caudal fin Fig. 5 from Meng et al., 2016
tg control Fig. 7 from Opitz et al., 2011
tgfb1a chemical treatment: vascular endothelial growth factor receptor antagonist Fig. 4 with image from Monteiro et al., 2016
tgfb1b chemical treatment: vascular endothelial growth factor receptor antagonist Fig. 4 with image from Monteiro et al., 2016
tgfb2 standard conditions Fig. 7 with image from Swartz et al., 2011
tgfb3 standard conditions Fig. 7 with image from Swartz et al., 2011
tgfbr3 control Fig. 3 with imageFig. 5 with image from Kamaid et al., 2015
thsd7aa standard conditions Fig. 5 with image from Wang et al., 2011
tjp1a control Fig. 2 from Alvarez et al., 2010
chemical treatment: glucose Fig. 2 from Alvarez et al., 2010
tln1 standard conditions Fig. 5 with image from James et al., 2016
tmem88a standard conditions Fig. 3 from Eve et al., 2017
tmem88b standard conditions Fig. 7 with image from Eve et al., 2017
tmem184a standard conditions Fig. 1 with image from Farwell et al., 2017
amputation: caudal fin Fig. 1 with image from Farwell et al., 2017
tp53 control Fig. 4 with image from Espín et al., 2013
vegfaa standard conditions Fig. 6 with image from Xu et al., 2012
Fig. 2 from Alvarez et al., 2010
chemical treatment: glucose Fig. 2 from Alvarez et al., 2010
vegfab control Fig. 4 with image from Oehlers et al., 2011
chemical treatment: pharmaceutical Fig. 4 with image from Oehlers et al., 2011
Protein expression
Antibody Antigen Genes Structure Conditions Figures
Ab1-hoxc9 standard conditions Fig. S6 from Stoll et al., 2011
Ab1-mef2 resection: cardiac ventricle Fig. 3Fig. 4 from Missinato et al., 2015
Ab2-lcp1 viral treatment: Carp sprivivirus Fig. 1Fig. 5 from Varela et al., 2014
Ab3-smad2 standard conditions Fig. 4Fig. 5 from Flanagan-Steet et al., 2016
Ab1-podxl2 standard conditions Fig. 6 with image from Sauteur et al., 2017
Fig. 3 from Hultin et al., 2014
Fig. 8 from Hayashi et al., 2013
Ab10-prox1 standard conditions Fig. 3 with imageFig. 4 with imageFig. 7 with image from Shin et al., 2016
Ab1-col2a chemical treatment: pharmaceutical Fig. 4 with image from Ning et al., 2013
zn-8 standard conditions Fig. 2 from Lin et al., 2013
Fig. 8 with image from Huang et al., 2009
Fig. 4 from Kucenas et al., 2009
Ab4-GFP standard conditions Fig. 4 with imageFig. 5 with image from James et al., 2016
Ab5-GFP standard conditions Fig. 1 with image from Farwell et al., 2017
Ab-A4.1025 standard conditions Fig. S5 from Nguyen et al., 2014
Fig. S4 with image from Hinits et al., 2012
Ab1-ctsk standard conditions Fig. 6 from Flanagan-Steet et al., 2016
Fig. 5 with image from Petrey et al., 2012
Ab7-mapk standard conditions Fig. 3 with image from Christie et al., 2010
Ab3-dag1 standard conditions Fig. 3 from Wood et al., 2011
Ab1-cldn5 standard conditions Fig. 3 with image from Wang et al., 2014
Ab2-pcna standard conditions Fig. 3 from Duy et al., 2017
Fig. S8 with image from Cheng et al., 2016
Ab3-lcp1 chemical treatment by environment: pentetrazol Fig. 2Fig. 3 from Duy et al., 2017
zn-12 standard conditions Fig. 5 with image from Krueger et al., 2011
Ab5-prox1 standard conditions Fig. 4 with image from Kärpanen et al., 2017
Ab2-pcna chemical treatment by environment: pentetrazol Fig. 3 from Duy et al., 2017
zrf-1 standard conditions Fig. S3 with image from Fleming et al., 2013
Ab1-abcb1/4/5 standard conditions Fig. 3 with imageFig. S2 with image from Fleming et al., 2013
Ab1-vegfc physical alteration: anatomical structure Fig. 5 with image from Khatib et al., 2010
zns-5 standard conditions Fig. 7 with image from Huang et al., 2009
Ab-F59 resection: cardiac ventricle Fig. 6 from Missinato et al., 2015
Ab5-GFP amputation: caudal fin Fig. 1 with image from Farwell et al., 2017
Ab-MF20 standard conditions Fig. 5 with image from Cheng et al., 2016
Ab1-gipc standard conditions Fig. 1 from Hermans et al., 2010
Ab10-prox1 chemical treatment by environment: SL-327 Fig. 4 with image from Shin et al., 2016
znp-1 standard conditions Fig. 6 with image from Kwon et al., 2013
Ab1-tjp1 standard conditions 12 figures with image from 6 publications
Ab11-smad standard conditions Fig. 4 from Flanagan-Steet et al., 2016
zn-5 chemical treatment: glucose Fig. 4 from Alvarez et al., 2010
Ab1-smad standard conditions Fig. 4Fig. 5 from Flanagan-Steet et al., 2016
Ab2-smad2/3 standard conditions Fig. 4 from Flanagan-Steet et al., 2016
Ab1-tmem184a amputation: caudal fin Fig. 1 with image from Farwell et al., 2017
Ab1-cdh5 chemical treatment: pharmaceutical Fig. 3 with image from De Smet et al., 2014
Ab1-esama control Fig. 5 from Sauteur et al., 2014
zpr-3 chemical treatment: glucose Fig. 4 from Alvarez et al., 2010
Ab4-h3 control Fig. 5 with image from Kara et al., 2017
Ab-T4 control Fig. 7Fig. 8 from Opitz et al., 2011
Ab1-tmem184a standard conditions Fig. 1 with image from Farwell et al., 2017
Ab1-casp3 control Fig. 6 from Craig et al., 2015
Ab1-tjp1 chemical treatment: pharmaceutical Fig. 5 from Sauteur et al., 2014
Ab1-lama1 standard conditions Fig. 4 with image from James et al., 2016
Fig. 3 from Hultin et al., 2014
Ab1-lama2 standard conditions text only from Zygmunt et al., 2011
Ab1-dag1 standard conditions Fig. 3 from Wood et al., 2011
zpr-1 control Fig. 4Fig. 5 from Alvarez et al., 2010
Ab1-pan-Cadherin standard conditions Fig. S3 from Eberhart et al., 2008
zpr-1 chemical treatment: glucose Fig. 4Fig. 5 from Alvarez et al., 2010
zn-5 standard conditions Fig. S5 with image from Ning et al., 2013
Fig. 4 from Alvarez et al., 2010
Fig. 2 with image from Schwend et al., 2009
Ab1-col2a standard conditions Fig. 2 with imageFig. 4 with image from Ning et al., 2013
Fig. 4 from Flanagan-Steet et al., 2009
zpr-3 control Fig. 4 from Alvarez et al., 2010
Ab2-lcp1 control Fig. 1 from Varela et al., 2014
Ab1-esama chemical treatment: pharmaceutical Fig. 5 from Sauteur et al., 2014
Ab9-mapk standard conditions Fig. 4 with image from Kärpanen et al., 2017
Fig. 4 with image from Shin et al., 2016
Fig. 4 with image from Le Guen et al., 2014
Fig. 8 from Yu et al., 2010
Ab1-cdh5 cdh5 standard conditions Fig. 3 with image from De Smet et al., 2014
Fig. S1 from Sauteur et al., 2014
Fig. 8 from Hayashi et al., 2013
Fig. 6 with image from Carra et al., 2012
Fig. 1 with image from Herwig et al., 2011
Fig. 7 with imageFig. 8 with image from Wang et al., 2010
Fig. 3 with imageFig. 4 with image from Blum et al., 2008
Ab1-cyp1a cyp1a chemical treatment: pharmaceutical Fig. 2Fig. 3 from Incardona et al., 2011
Ab3-GFP EGFP standard conditions Fig. 3 from Hogan et al., 2008
Ab1-GFP GFP chemical treatment: pharmaceutical Fig. 2Fig. 3 from Incardona et al., 2011
Ab1-hmgb1a hmgb1a control Fig. 4 from Fang et al., 2014
Ab1-hmgb1a physical alteration: spinal cord Fig. 4 from Fang et al., 2014
Ab3-lcp1 lcp1 control Fig. 2Fig. 3 from Duy et al., 2017
Fig. 4 with image from Jin et al., 2009
Ab1-meox1 meox1 standard conditions Fig. 2Fig. S3 from Nguyen et al., 2014
Ab1-mlc1 mlc1 standard conditions Fig. 4 from Sirisi et al., 2014
Ab1-nostrin nostrin control Fig. 1 from Kovacevic et al., 2012
Ab1-ntn4 ntn4 control Fig. 1 from Lambert et al., 2012
Ab1-pdgfrb pdgfrb standard conditions Fig. 2 with image from Kok et al., 2015
Ab1-tg tg control Fig. 7 from Opitz et al., 2011
Ab1-tgfbr3 tgfbr3 control Fig. 3 with imageFig. 5 with image from Kamaid et al., 2015
Ab2-tmem184a tmem184a standard conditions Fig. 1 with image from Farwell et al., 2017
Ab2-tmem184a amputation: caudal fin Fig. 1 with image from Farwell et al., 2017
Ab1-tp53 tp53 control Fig. 4 with image from Espín et al., 2013
Reporter gene expression
Expressed Gene Structure Conditions Figures
EGFP standard conditions 355 figures with image from 187 publications
chemical treatment: pharmaceutical 48 figures with image from 30 publications
physical alteration: anatomical structure 69 figures with image from 42 publications
GFP standard conditions Fig. 5 from Tonon et al., 2016
Fig. 2 with image from Zaucker et al., 2013
Fig. 4 with image from Murphy et al., 2010
chemical treatment: semaxanib Fig. 2Fig. 3 from Incardona et al., 2011
Fig. 3 with imageFig. 4 with imageFig. S3 with image from Murphy et al., 2010
bacterial treatment by injection: Escherichia coli Fig. 7 from Itou et al., 2017
Fig. 2 with image from Barber et al., 2016
Fig. 2 with image from Mercatali et al., 2016
Fig. 5 from Tonon et al., 2016
PHENOTYPE
Phenotype in y1Tg
Phenotype Conditions Figures
angiogenesis disrupted, abnormal chemical treatment: LY294002 Fig. 1 with image from Alvarez et al., 2009
angiogenesis disrupted, abnormal chemical treatment: butan-1-ol Fig. 7 with image from Zeng et al., 2009
angiogenesis disrupted, abnormal chemical treatment: pharmaceutical Fig. 4 from Cho et al., 2013
angiogenesis increased occurrence, abnormal cancer xenotransplantation Fig. 1 from Baltrunaite et al., 2017
angiogenesis increased occurrence, abnormal cancer xenotransplantation Fig. 6 from Würth et al., 2017
angiogenesis involved in wound healing disrupted, abnormal amputation: caudal fin, chemical treatment: LY294002 Fig. 6 with image from Alvarez et al., 2009
angiogenesis involved in wound healing process quality, abnormal amputation: fin, chemical treatment: pharmaceutical, chemical treatment: cobalt dichloride, hypoxia Fig. 6 from Eyries et al., 2008
angiogenesis involved in wound healing process quality, normal amputation: fin, chemical treatment: pharmaceutical Fig. 6 from Eyries et al., 2008
angiogenic sprout decreased length, abnormal chemical treatment: pharmaceutical Fig. 4 from Cho et al., 2013
atrioventricular canal cell proliferation decreased process quality, abnormal chemical treatment: pharmaceutical Fig. S5 from Banjo et al., 2013
atrioventricular canal cell proliferation decreased process quality, abnormal chemical treatment: pharmaceutical Fig. S5 from Banjo et al., 2013
atrioventricular valve hypoplastic, abnormal chemical treatment by environment: ethanol Fig. 1 with image from Sarmah et al., 2016
atrioventricular valve morphology, abnormal chemical treatment by environment: ethanol Fig. 1 with image from Sarmah et al., 2016
blood circulation decreased occurrence, abnormal chemical treatment by injection: agarose, physical alteration: intersegmental vessel Fig. 1 from Choi et al., 2017
blood circulation decreased process quality, abnormal bacterial treatment by injection: Waddlia chondrophila WSU 86-1044 Fig. 4 with image from Fehr et al., 2016
blood circulation disrupted, abnormal chemical treatment: herbicide Fig. 5 with image from Kalén et al., 2009
blood island cell death increased process quality, abnormal viral treatment: Carp sprivivirus Fig. 2 from Varela et al., 2014
blood vasculature broken, abnormal chemical treatment: herbicide Fig. 5 with image from Kalén et al., 2009
blood vessel mcamb expression increased amount, abnormal transection: spinal cord Fig. 4 from Liu et al., 2016
blood vessel increased branchiness, abnormal chemical treatment: pharmaceutical Fig. 1Fig. 5Fig. 6 from Jörgens et al., 2015
blood vessel increased branchiness, abnormal chemical treatment: pharmaceutical Fig. 1Fig. 5Fig. 6 from Jörgens et al., 2015
blood vessel increased branchiness, abnormal chemical treatment: pharmaceutical Fig. 1 from Jörgens et al., 2015
blood vessel malformed, abnormal chemical treatment: pharmaceutical Fig. 6 from Pruvot et al., 2014
blood vessel morphology, abnormal chemical treatment: pharmaceutical Fig. 3Fig. 7 from Chen et al., 2012
blood vessel morphology, abnormal chemical treatment: pharmaceutical Fig. 1Fig. 5Fig. 6 from Jörgens et al., 2015
blood vessel morphology, abnormal chemical treatment: pharmaceutical Fig. 1 from Jörgens et al., 2015
blood vessel morphology, abnormal chemical treatment: pharmaceutical Fig. 1Fig. 5Fig. 6 from Jörgens et al., 2015
blood vessel endothelial cell tgfb1b expression decreased amount, abnormal chemical treatment: vascular endothelial growth factor receptor antagonist Fig. 4 with image from Monteiro et al., 2016
blood vessel endothelial cell tgfb1a expression decreased amount, abnormal chemical treatment: vascular endothelial growth factor receptor antagonist Fig. 4 with image from Monteiro et al., 2016
blood vessel endothelial cell kdrl expression decreased amount, abnormal chemical treatment: vascular endothelial growth factor receptor antagonist Fig. 4 with image from Monteiro et al., 2016
blood vessel endothelial cell cell-cell junction decreased amount, abnormal chemical treatment: pharmaceutical Fig. 3 with image from De Smet et al., 2014
brain neoplastic, abnormal cancer xenotransplantation, chemical treatment: dexamethasone Fig. 3 from Eden et al., 2015
branching involved in blood vessel morphogenesis process quality, normal chemical treatment: drug Fig. S2 with image from Eisa-Beygi et al., 2013
branching morphogenesis of an epithelial tube disrupted, abnormal chemical treatment: herbicide Fig. 5 with image from Kalén et al., 2009
cardiac muscle tissue regeneration decreased process quality, abnormal chemical treatment: 4-methylumbelliferone, resection: cardiac ventricle Fig. 3 from Missinato et al., 2015
caudal artery morphology, normal standard conditions Fig. 4 with image from Liu et al., 2008
caudal fin morphology, abnormal chemical treatment by environment: Fadrozole hydrochloride Fig. 4 from Alharthy et al., 2017
caudal fin morphology, abnormal chemical treatment by environment: benzo[a]pyrene Fig. 4 from Alharthy et al., 2017
caudal fin morphology, ameliorated chemical treatment by environment: Fadrozole hydrochloride, chemical treatment by environment: 17beta-estradiol Fig. 4 from Alharthy et al., 2017
caudal fin morphology, exacerbated chemical treatment by environment: benzo[a]pyrene, chemical treatment by environment: 17beta-estradiol Fig. 4 from Alharthy et al., 2017
caudal vein morphology, normal standard conditions Fig. 4 with image from Liu et al., 2008
caudal vein blood circulation absent, abnormal chemical treatment: pharmaceutical Fig. 6 from Pruvot et al., 2014
caudal vein blood circulation absent, abnormal chemical treatment: pharmaceutical Fig. 6 from Pruvot et al., 2014
caudal vein blood circulation decreased process quality, abnormal chemical treatment: pharmaceutical Fig. 6 from Pruvot et al., 2014
caudal vein plexus decreased width, abnormal chemical treatment: pharmaceutical Fig. 5 with image from Wakayama et al., 2015
caudal vein plexus decreased width, abnormal chemical treatment: pharmaceutical Fig. 1 with image from Wakayama et al., 2015
caudal vein plexus malformed, abnormal chemical treatment: pharmaceutical Fig. 5 with image from Wakayama et al., 2015
caudal vein plexus morphology, abnormal chemical treatment: pharmaceutical Fig. 7 with image from Huang et al., 2008
caudal vein plexus morphology, abnormal chemical treatment: pharmaceutical Fig. 4 with image from De Smet et al., 2014
caudal vein plexus morphology, normal chemical treatment: semaxanib Fig. 9 with image from Ben Shoham et al., 2012
caudal vein plexus blood vessel development process quality, abnormal chemical treatment: pharmaceutical Fig. 4 with image from De Smet et al., 2014
caudal vein plexus sprouting angiogenesis process quality, abnormal chemical treatment: pharmaceutical Fig. 1 with image from Wakayama et al., 2015
ceratobranchial 5 replacement tooth dissociated from pharyngeal arch 7 blood vessel, abnormal chemical treatment: semaxanib Fig. 4 from Crucke et al., 2015
ceratobranchial 5 replacement tooth odontogenesis rate, normal chemical treatment: semaxanib Fig. 2 from Crucke et al., 2015
ceratobranchial 5 replacement tooth odontogenesis variability of rate, abnormal chemical treatment: semaxanib Fig. 3 from Crucke et al., 2015
ceratohyal cartilage chondroblast disorganized, abnormal chemical treatment: pharmaceutical Fig. 4 with image from Ning et al., 2013
ceratohyal cartilage chondrocyte differentiation process quality, abnormal chemical treatment: pharmaceutical Fig. 4 with image from Ning et al., 2013
dorsal aorta broken, abnormal chemical treatment by environment: ethanol Fig. 3 with image from Li et al., 2016
dorsal aorta decreased width, abnormal chemical treatment by environment: ethanol Fig. 2 with image from Li et al., 2016
dorsal aorta morphology, normal standard conditions Fig. 4 with image from Liu et al., 2008
dorsal aorta blood vessel endothelial cell decreased length, abnormal chemical treatment: blebbistatin Fig. 8 from Hultin et al., 2014
dorsal aorta blood vessel lumenization decreased process quality, abnormal chemical treatment: blebbistatin Fig. 8 from Hultin et al., 2014
dorsal aorta endothelial cell morphogenesis decreased process quality, abnormal chemical treatment: blebbistatin Fig. 8 from Hultin et al., 2014
dorsal aorta morphogenesis decreased process quality, abnormal chemical treatment: blebbistatin Fig. 8 from Hultin et al., 2014
dorsal longitudinal anastomotic vessel aplastic, abnormal chemical treatment: pharmaceutical Fig. 5 from Lee et al., 2014
dorsal longitudinal anastomotic vessel aplastic, abnormal chemical treatment: pharmaceutical Fig. 1 from Lee et al., 2014
dorsal longitudinal anastomotic vessel aplastic, abnormal chemical treatment: pharmaceutical Fig. 1 from Lee et al., 2014
dorsal longitudinal anastomotic vessel constricted, abnormal chemical treatment by environment: Diacetylmonoxime Fig. 7 with image from Nakajima et al., 2017
dorsal longitudinal anastomotic vessel disassembled, abnormal chemical treatment: pharmaceutical Fig. 2 with image from De Smet et al., 2014
dorsal longitudinal anastomotic vessel hypoplastic, abnormal chemical treatment: antagonist Fig. 1 from Chen et al., 2017
dorsal longitudinal anastomotic vessel malformed, abnormal standard conditions Fig. 1 from Jiang et al., 2013
dorsal longitudinal anastomotic vessel morphology, abnormal chemical treatment by environment: Diacetylmonoxime Fig. 7 with image from Nakajima et al., 2017
dorsal longitudinal anastomotic vessel blood circulation absent, abnormal chemical treatment: pharmaceutical Fig. 6 from Pruvot et al., 2014
dorsal longitudinal anastomotic vessel blood circulation absent, abnormal chemical treatment: pharmaceutical Fig. 6 from Pruvot et al., 2014
dorsal longitudinal anastomotic vessel endothelial cell detached from dorsal longitudinal anastomotic vessel endothelial cell, abnormal chemical treatment: pharmaceutical Fig. 2 with image from De Smet et al., 2014
embryonic pectoral fin morphogenesis process quality, abnormal chemical treatment: thalidomide Fig. S18 from Ito et al., 2010
endocardial cushion aplastic, abnormal chemical treatment: pharmaceutical Fig. 4 from Banjo et al., 2013
epithelial cell protruding, abnormal bacterial treatment by injection: Escherichia coli Fig. 2 with image from Barber et al., 2016
eye decreased size, abnormal chemical treatment by environment: Fadrozole hydrochloride, chemical treatment by environment: 17beta-estradiol Fig. 3 from Alharthy et al., 2017
eye decreased size, abnormal chemical treatment by environment: 17beta-estradiol Fig. 3 from Alharthy et al., 2017
eye decreased size, abnormal chemical treatment by environment: benzo[a]pyrene, chemical treatment by environment: 17beta-estradiol Fig. 3 from Alharthy et al., 2017
eye decreased size, abnormal chemical treatment by environment: benzo[a]pyrene Fig. 3 from Alharthy et al., 2017
eye decreased size, abnormal chemical treatment by environment: Fadrozole hydrochloride Fig. 3 from Alharthy et al., 2017
fin regeneration disrupted, abnormal amputation: caudal fin, chemical treatment by injection: heparin Fig. 7 from Farwell et al., 2017
gut angiogenesis decreased occurrence, abnormal chemical treatment by injection: docosahexaenoic acid Fig. 4 with image from Wang et al., 2016
gut blood vasculature decreased branchiness, abnormal chemical treatment by injection: docosahexaenoic acid Fig. 4 with image from Wang et al., 2016
hatching decreased occurrence, abnormal chemical treatment by environment: Fadrozole hydrochloride, chemical treatment by environment: 17beta-estradiol Fig. 2 from Alharthy et al., 2017
hatching decreased occurrence, abnormal chemical treatment by environment: benzo[a]pyrene, chemical treatment by environment: 17beta-estradiol Fig. 2 from Alharthy et al., 2017
hatching decreased occurrence, abnormal chemical treatment by environment: Fadrozole hydrochloride Fig. 2 from Alharthy et al., 2017
hatching decreased occurrence, abnormal chemical treatment by environment: benzo[a]pyrene Fig. 2 from Alharthy et al., 2017
heart straight, abnormal chemical treatment by environment: ethanol Fig. 1 with image from Sarmah et al., 2016
heart contraction arrested, abnormal chemical treatment by environment: Diacetylmonoxime Fig. 7 with image from Nakajima et al., 2017
heart contraction increased rate, abnormal chemical treatment by environment: ethanol Fig. 1 with image from Sarmah et al., 2016
heart valve development disrupted, abnormal chemical treatment: pharmaceutical Fig. 4 from Banjo et al., 2013
hyaloid vessel branchiness, abnormal chemical treatment: LY294002 Fig. 5 with image from Alvarez et al., 2009
hyaloid vessel decreased branchiness, abnormal chemical treatment: SH-11037 Fig. 2 with image from Sulaiman et al., 2016
hyaloid vessel irregular spatial pattern, abnormal chemical treatment: LY294002 Fig. 1 with imageFig. 4 with image from Alvarez et al., 2009
hyaloid vessel irregular spatial pattern, abnormal chemical treatment: EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor Fig. 4 with image from Alvarez et al., 2009
hyaloid vessel angiogenesis decreased occurrence, abnormal chemical treatment: SH-11037 Fig. 2 with image from Sulaiman et al., 2016
hyaloid vessel sprouting angiogenesis decreased process quality, abnormal chemical treatment: pharmaceutical Fig. 5 with image from Sasore et al., 2014
hyaloid vessel sprouting angiogenesis decreased process quality, abnormal chemical treatment: pharmaceutical Fig. 5 with image from Sasore et al., 2014
hyaloid vessel sprouting angiogenesis decreased process quality, abnormal chemical treatment: pharmaceutical Fig. 5 with image from Sasore et al., 2014
hyaloid vessel sprouting angiogenesis decreased process quality, abnormal chemical treatment: pharmaceutical Fig. 5 with image from Sasore et al., 2014
hyaloid vessel sprouting angiogenesis decreased process quality, abnormal chemical treatment: pharmaceutical Fig. 5 with image from Sasore et al., 2014
hyaloid vessel sprouting angiogenesis decreased process quality, abnormal chemical treatment: pharmaceutical Fig. 5 with image from Sasore et al., 2014
hyaloid vessel sprouting angiogenesis decreased process quality, abnormal chemical treatment: pharmaceutical Fig. 5 with image from Sasore et al., 2014
intersegmental artery absent, abnormal angiogenesis inhibitor: anti-angiogenic agent Fig. 4 from Venkateswaran et al., 2014
intersegmental artery decreased width, abnormal chemical treatment by environment: ethanol Fig. 2 with image from Li et al., 2016
intersegmental artery morphology, abnormal chemical treatment by environment: ethanol Fig. 3 with image from Li et al., 2016
intersegmental vein absent, abnormal angiogenesis inhibitor: anti-angiogenic agent Fig. 4 from Venkateswaran et al., 2014
intersegmental vessel aplastic, abnormal chemical treatment: vascular endothelial growth factor receptor antagonist Fig. 4 with image from Monteiro et al., 2016
intersegmental vessel aplastic, abnormal chemical treatment: wortmannin Fig. S8 with image from Liu et al., 2008
intersegmental vessel aplastic, abnormal chemical treatment: U0126 Fig. S8 with image from Liu et al., 2008
intersegmental vessel brochidodromous, abnormal chemical treatment: wortmannin Fig. S8 with image from Liu et al., 2008
intersegmental vessel brochidodromous, abnormal chemical treatment: U0126 Fig. S8 with image from Liu et al., 2008
intersegmental vessel collapsed, abnormal chemical treatment: pharmaceutical Fig. 2 with image from De Smet et al., 2014
intersegmental vessel decreased branchiness, abnormal standard conditions Fig. 1 from Jiang et al., 2013
intersegmental vessel decreased functionality, abnormal chemical treatment: herbicide Fig. 5 with image from Kalén et al., 2009
intersegmental vessel decreased length, abnormal chemical treatment: pharmaceutical Fig. 4 from Cho et al., 2013
intersegmental vessel disassembled, abnormal chemical treatment: pharmaceutical Fig. 2 with image from De Smet et al., 2014
intersegmental vessel disorganized, abnormal chemical treatment: wortmannin Fig. S8 with image from Liu et al., 2008
intersegmental vessel disorganized, abnormal chemical treatment: U0126 Fig. S8 with image from Liu et al., 2008
intersegmental vessel disorganized, abnormal chemical treatment: DAPT Fig. 4 with image from Jensen et al., 2012
intersegmental vessel has extra parts of type blood vessel, abnormal chemical treatment: DAPT Fig. 4 with image from Jensen et al., 2012
intersegmental vessel has extra parts of type vascular sprouts, abnormal chemical treatment: DAPT Fig. 4 with image from Jensen et al., 2012
intersegmental vessel hypoplastic, abnormal chemical treatment: antagonist Fig. 1 from Chen et al., 2017
intersegmental vessel immature, abnormal chemical treatment by environment: semaxanib Fig. S10 with image from Fu et al., 2017
intersegmental vessel immature, abnormal chemical treatment: semaxanib Fig. 1 from Crucke et al., 2015
intersegmental vessel increased mass density, abnormal chemical treatment: DAPT Fig. 4 with image from Jensen et al., 2012
intersegmental vessel malformed, abnormal chemical treatment: pharmaceutical Fig. 1 from Lee et al., 2014
intersegmental vessel malformed, abnormal chemical treatment: pharmaceutical Fig. 5 from Lee et al., 2014
intersegmental vessel malformed, abnormal chemical treatment: pharmaceutical Fig. 1 from Lee et al., 2014
intersegmental vessel morphology, abnormal chemical treatment: pharmaceutical Fig. 1 from Jörgens et al., 2015
intersegmental vessel morphology, abnormal chemical treatment: pharmaceutical Fig. 1Fig. 5Fig. 6 from Jörgens et al., 2015
intersegmental vessel morphology, abnormal radiation Fig. 5Fig. 6Fig. 7 from Dong et al., 2008
intersegmental vessel morphology, abnormal chemical treatment: pharmaceutical Fig. 3Fig. 7 from Chen et al., 2012
intersegmental vessel morphology, abnormal chemical treatment: pharmaceutical Fig. 1Fig. 5Fig. 6 from Jörgens et al., 2015
intersegmental vessel morphology, abnormal chemical treatment: butan-1-ol Fig. 7 with image from Zeng et al., 2009
intersegmental vessel morphology, normal standard conditions Fig. 4 with image from Liu et al., 2008
intersegmental vessel shortened, abnormal constant light Fig. 1 with image from Jensen et al., 2012
intersegmental vessel structure, abnormal chemical treatment: pharmaceutical Fig. 1Fig. 5Fig. 6 from Jörgens et al., 2015
intersegmental vessel structure, abnormal chemical treatment: pharmaceutical Fig. 1 from Jörgens et al., 2015
intersegmental vessel structure, abnormal chemical treatment: pharmaceutical Fig. 1Fig. 5Fig. 6 from Jörgens et al., 2015
intersegmental vessel blood circulation absent, abnormal chemical treatment: pharmaceutical Fig. 6 from Pruvot et al., 2014
intersegmental vessel blood circulation absent, abnormal chemical treatment: pharmaceutical Fig. 6 from Pruvot et al., 2014
intersegmental vessel blood circulation absent, abnormal chemical treatment: pharmaceutical Fig. 6 from Pruvot et al., 2014
intersegmental vessel cell junction morphology, abnormal chemical treatment: pharmaceutical Fig. 5 from Sauteur et al., 2014
intersegmental vessel cell junction morphology, abnormal chemical treatment: pharmaceutical Fig. 5 from Sauteur et al., 2014
intersegmental vessel endothelial cell decreased adhesivity, abnormal chemical treatment: pharmaceutical Fig. 3 with image from De Smet et al., 2014
intersegmental vessel endothelial cell detached from intersegmental vessel endothelial cell, abnormal chemical treatment: pharmaceutical Fig. 2 with image from De Smet et al., 2014
intersegmental vessel filopodium decreased size, abnormal standard conditions Fig. 1 from Jiang et al., 2013
intersegmental vessel sprouting angiogenesis decreased occurrence, abnormal chemical treatment: antagonist Fig. 1 from Chen et al., 2017
intersegmental vessel sprouting angiogenesis decreased process quality, abnormal chemical treatment: pharmaceutical Fig. 3 with image from Sasore et al., 2014
intersegmental vessel sprouting angiogenesis decreased process quality, abnormal chemical treatment: pharmaceutical Fig. 3 with image from Sasore et al., 2014
intersegmental vessel sprouting angiogenesis decreased process quality, abnormal chemical treatment: pharmaceutical Fig. 3 with image from Sasore et al., 2014
intersegmental vessel sprouting angiogenesis decreased process quality, abnormal chemical treatment: pharmaceutical Fig. 3 with image from Sasore et al., 2014
intersegmental vessel sprouting angiogenesis decreased process quality, abnormal chemical treatment: pharmaceutical Fig. 3 with image from Sasore et al., 2014
intersegmental vessel unidimensional cell growth process quality, abnormal chemical treatment: pharmaceutical Fig. 5 from Sauteur et al., 2014
intestine blood vessel decreased branchiness, abnormal standard conditions Fig. 1 from Jiang et al., 2013
intestine vasculature branchiness, abnormal chemical treatment: pharmaceutical Fig. 4 with image from Oehlers et al., 2011
intestine vasculature structure, normal chemical treatment: pharmaceutical Fig. 4 with image from Oehlers et al., 2011
lateral zone of dorsal telencephalon blood cell dilated, abnormal chemical treatment by environment: pentetrazol Fig. 2 from Duy et al., 2017
lateral zone of dorsal telencephalon leukocyte increased amount, abnormal chemical treatment by environment: pentetrazol Fig. 2 from Duy et al., 2017
liver vasculature dilated, abnormal chemical treatment: ethanol Fig. S2 from Howarth et al., 2013
lymphangiogenic sprout Ab10-prox1 labeling absent, abnormal chemical treatment by environment: SL-327 Fig. 4 with image from Shin et al., 2016
lymphangiogenic sprout absent, abnormal chemical treatment by environment: SL-327 Fig. 4 with image from Shin et al., 2016
MAPK cascade disrupted, abnormal chemical treatment: 2-(2-amino-3-methoxyphenyl)chromen-4-one Fig. 4 with image from Le Guen et al., 2014
motor neuron axon guidance process quality, normal chemical treatment: butan-1-ol Fig. 7 with image from Zeng et al., 2009
ocular blood vessel decreased amount, abnormal chemical treatment: EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor Fig. 4 with image from Alvarez et al., 2009
ocular blood vessel decreased amount, abnormal chemical treatment: LY294002 Fig. 1 with imageFig. 4 with imageFig. 5 with image from Alvarez et al., 2009
ocular blood vessel increased thickness, abnormal chemical treatment: glucose Fig. 1 from Alvarez et al., 2010
ocular blood vessel adherens junction increased width, abnormal chemical treatment: D-mannitol Fig. 2 from Alvarez et al., 2010
ocular blood vessel adherens junction increased width, abnormal chemical treatment: glucose Fig. 2 from Alvarez et al., 2010
ocular blood vessel basement membrane increased thickness, abnormal chemical treatment: glucose Fig. 2 from Alvarez et al., 2010
ocular blood vessel bicellular tight junction increased width, abnormal chemical treatment: glucose Fig. 2 from Alvarez et al., 2010
ocular blood vessel bicellular tight junction increased width, abnormal chemical treatment: D-mannitol Fig. 2 from Alvarez et al., 2010
optic artery vascular endothelium increased thickness, abnormal high cholesterol, high glucose Fig. 2 with image from Wang et al., 2013
optic artery vascular endothelium thickness, ameliorated chemical treatment: metformin, high cholesterol, high glucose Fig. 2 with image from Wang et al., 2013
optic artery vascular endothelium thickness, ameliorated chemical treatment: pioglitazone, high cholesterol, high glucose Fig. 2 with image from Wang et al., 2013
optokinetic behavior occurrence, normal chemical treatment: LY294002 Fig. 8 with image from Alvarez et al., 2009
palatoquadrate cartilage chondroblast disorganized, abnormal chemical treatment: pharmaceutical Fig. 4 with image from Ning et al., 2013
palatoquadrate cartilage chondrocyte differentiation process quality, abnormal chemical treatment: pharmaceutical Fig. 4 with image from Ning et al., 2013
parachordal vessel absent, abnormal chemical treatment by environment: SL-327 Fig. 4 with image from Shin et al., 2016
parachordal vessel vasculature development decreased occurrence, abnormal chemical treatment by environment: SL-327 Fig. 4 with image from Shin et al., 2016
pectoral fin morphology, abnormal chemical treatment by environment: benzo[a]pyrene Fig. 4 from Alharthy et al., 2017
pectoral fin morphology, exacerbated chemical treatment by environment: benzo[a]pyrene, chemical treatment by environment: 17beta-estradiol Fig. 4 from Alharthy et al., 2017
pectoral fin blood vessel aplastic, abnormal chemical treatment: thalidomide Fig. S18 from Ito et al., 2010
pectoral fin bud decreased size, abnormal chemical treatment: thalidomide Fig. S18 from Ito et al., 2010
pericardium edematous, abnormal chemical treatment by environment: Fadrozole hydrochloride Fig. 3 from Alharthy et al., 2017
pericardium edematous, abnormal chemical treatment by environment: benzo[a]pyrene Fig. 3 from Alharthy et al., 2017
pericardium edematous, abnormal bacterial treatment by injection: Waddlia chondrophila WSU 86-1044 Fig. 4 with image from Fehr et al., 2016
pericardium edematous, abnormal chemical treatment: SH-11037 Fig. 2 with image from Sulaiman et al., 2016
pericardium edematous, ameliorated chemical treatment by environment: Fadrozole hydrochloride, chemical treatment by environment: 17beta-estradiol Fig. 3 from Alharthy et al., 2017
pericardium edematous, ameliorated chemical treatment by environment: benzo[a]pyrene, chemical treatment by environment: 17beta-estradiol Fig. 3 from Alharthy et al., 2017
phagocytosis process quality, normal fungal treatment by injection: Candida albicans Fig. 2 from Brothers et al., 2011
pharyngeal arch cell proliferation decreased process quality, abnormal chemical treatment: pharmaceutical Fig. 4 with image from Ning et al., 2013
post-vent region neoplasm increased amount, abnormal cancer xenotransplantation Fig. 1 from Baltrunaite et al., 2017
posterior cardinal vein morphology, normal standard conditions Fig. 4 with image from Liu et al., 2008
posterior caudal vein vascular sprouts absent, abnormal chemical treatment by environment: SL-327 Fig. 4 with image from Shin et al., 2016
primary motor neuron branched, abnormal chemical treatment: butan-1-ol Fig. 7 with image from Zeng et al., 2009
regenerating fin lmo2 expression increased amount, abnormal resection: caudal fin Fig. 5 from Meng et al., 2016
regenerating fin tek expression increased amount, abnormal resection: caudal fin Fig. 5 from Meng et al., 2016
regenerating fin angiogenesis decreased process quality, abnormal amputation: caudal fin, chemical treatment: BGJ-398 Fig. 5 with image from De Smet et al., 2014
regenerating fin angiogenic sprout increased amount, abnormal amputation: caudal fin, chemical treatment by environment: cobalt dichloride Fig. 2 with image from Khatib et al., 2016
regenerating fin blood vessel remodeling decreased occurrence, abnormal amputation: caudal fin, chemical treatment by environment: cobalt dichloride Fig. 2 with image from Khatib et al., 2016
regenerating fin endothelial cell proliferation decreased occurrence, abnormal amputation: caudal fin, chemical treatment by injection: heparin Fig. 7 from Farwell et al., 2017
regenerating fin vasculature development disrupted, abnormal amputation: caudal fin, chemical treatment by injection: heparin Fig. 6 with imageFig. 7 from Farwell et al., 2017
regenerating tissue angiogenesis decreased occurrence, abnormal chemical treatment: 4-methylumbelliferone, resection: cardiac ventricle Fig. 3 from Missinato et al., 2015
regenerating tissue angiogenesis decreased occurrence, abnormal chemical treatment: inhibitor, resection: cardiac ventricle Fig. 6 from Missinato et al., 2015
regenerating tissue angiogenesis decreased occurrence, abnormal chemical treatment: tyrosine kinase inhibitor, resection: cardiac ventricle Fig. 6 from Missinato et al., 2015
regenerating tissue blood vessel aplastic, abnormal chemical treatment: pharmaceutical, physical alteration: anatomical structure Fig. 5 with image from Kim et al., 2010
regenerating tissue cardiac muscle cell decreased amount, abnormal chemical treatment: 4-methylumbelliferone, resection: cardiac ventricle Fig. 3 from Missinato et al., 2015
regenerating tissue endothelial cell absent, abnormal chemical treatment: pharmaceutical, physical alteration: anatomical structure Fig. 5 with image from Kim et al., 2010
regenerating tissue endothelial cell decreased amount, abnormal chemical treatment: 4-methylumbelliferone, resection: cardiac ventricle Fig. 3 from Missinato et al., 2015
regenerating tissue endothelial cell decreased amount, abnormal chemical treatment: inhibitor, resection: cardiac ventricle Fig. 6 from Missinato et al., 2015
regenerating tissue endothelial cell decreased amount, abnormal chemical treatment: tyrosine kinase inhibitor, resection: cardiac ventricle Fig. 6 from Missinato et al., 2015
retina ocular blood vessel decreased diameter, abnormal chemical treatment: cobalt dichloride Fig. 2 with image from Wu et al., 2015
retina ocular blood vessel decreased diameter, abnormal chemical treatment: GS4012 Fig. 2 with image from Wu et al., 2015
retina ocular blood vessel decreased diameter, abnormal chemical treatment: GS4012 Fig. 2 with image from Wu et al., 2015
retina ocular blood vessel disorganized, abnormal chemical treatment: GS4012 Fig. 2 with image from Wu et al., 2015
retina ocular blood vessel disorganized, abnormal chemical treatment: GS4012 Fig. 2 with image from Wu et al., 2015
retina ocular blood vessel increased amount, abnormal chemical treatment: cobalt dichloride Fig. 1 with image from Wu et al., 2015
retina ocular blood vessel increased branchiness, abnormal chemical treatment: GS4012 Fig. 2 with image from Wu et al., 2015
retina ocular blood vessel increased branchiness, abnormal chemical treatment: GS4012 Fig. 2 with image from Wu et al., 2015
retina ocular blood vessel increased branchiness, abnormal chemical treatment: cobalt dichloride Fig. 1 with imageFig. 2 with image from Wu et al., 2015
retina ocular blood vessel shape, abnormal chemical treatment: GS4012 Fig. 2 with image from Wu et al., 2015
retina ocular blood vessel shape, abnormal chemical treatment: GS4012 Fig. 2 with image from Wu et al., 2015
retina ocular blood vessel structure, abnormal chemical treatment: cobalt dichloride Fig. 3 with image from Wu et al., 2015
retina ocular blood vessel structure, abnormal chemical treatment: GS4012 Fig. 3 with image from Wu et al., 2015
retina vasculature development in camera-type eye increased process quality, abnormal chemical treatment: cobalt dichloride Fig. 1 with image from Wu et al., 2015
retina vasculature development in camera-type eye process quality, abnormal chemical treatment: cobalt dichloride Fig. 1 with image from Wu et al., 2015
retinal cone cell decreased length, abnormal chemical treatment: glucose Fig. 6 from Alvarez et al., 2010
retinal cone cell malformed, abnormal chemical treatment: glucose Fig. 6 from Alvarez et al., 2010
retinal cone cell morphology, abnormal chemical treatment: glucose Fig. 5 from Alvarez et al., 2010
retinal cone cell photoreceptor outer segment disorganized, abnormal chemical treatment: glucose Fig. 6 from Alvarez et al., 2010
retinal photoreceptor layer degenerate, abnormal chemical treatment: glucose Fig. 3 from Alvarez et al., 2010
sprouting angiogenesis decreased process quality, abnormal chemical treatment: pharmaceutical Fig. 2 with image from De Smet et al., 2014
sprouting angiogenesis disrupted, abnormal chemical treatment: semaxanib Fig. 2 with image from Leslie et al., 2007
sprouting angiogenesis disrupted, abnormal standard conditions Fig. 1 from Jiang et al., 2013
subintestinal vein absent, abnormal chemical treatment: semaxanib Fig. 1 from Crucke et al., 2015
subintestinal vein decreased branchiness, abnormal chemical treatment: peptide Fig. 3 with image from Zhou et al., 2015
subintestinal vein decreased branchiness, abnormal chemical treatment: polypeptide Fig. 3 with image from Zhou et al., 2015
subintestinal vein decreased size, abnormal constant light Fig. 1 with image from Jensen et al., 2012
subintestinal vein malformed, abnormal chemical treatment: cobalt dichloride Fig. 1 with image from Wu et al., 2015
subintestinal vein morphology, abnormal chemical treatment: pharmaceutical Fig. 4 with image from De Smet et al., 2014
subintestinal vein morphology, abnormal chemical treatment: semaxanib Fig. 9 with image from Ben Shoham et al., 2012
subintestinal vein morphology, normal standard conditions Fig. 4 with image from Liu et al., 2008
subintestinal vein blood vessel mislocalised, abnormal chemical treatment: cobalt dichloride Fig. 1 with image from Wu et al., 2015
subintestinal vein blood vessel development process quality, abnormal chemical treatment: pharmaceutical Fig. 4 with image from De Smet et al., 2014
subintestinal vein sprouting angiogenesis increased process quality, abnormal bacterial treatment, heat exposure Fig. 4 from Lima et al., 2014
subintestinal vein vascular sprouts increased amount, abnormal bacterial treatment, heat exposure Fig. 4 from Lima et al., 2014
swim bladder inflated, ameliorated chemical treatment by environment: Fadrozole hydrochloride, chemical treatment by environment: 17beta-estradiol Fig. 3 from Alharthy et al., 2017
swim bladder uninflated, abnormal chemical treatment by environment: 17beta-estradiol Fig. 3 from Alharthy et al., 2017
swim bladder uninflated, abnormal chemical treatment by environment: benzo[a]pyrene, chemical treatment by environment: 17beta-estradiol Fig. 3 from Alharthy et al., 2017
swim bladder uninflated, abnormal chemical treatment by environment: benzo[a]pyrene Fig. 3 from Alharthy et al., 2017
swim bladder uninflated, abnormal chemical treatment by environment: Fadrozole hydrochloride Fig. 3 from Alharthy et al., 2017
tissue regeneration disrupted, abnormal chemical treatment: pharmaceutical, physical alteration: anatomical structure Fig. 5 with image from Kim et al., 2010
tooth replacement decreased occurrence, abnormal chemical treatment: semaxanib Fig. 3Fig. 4 from Crucke et al., 2015
tooth replacement sporadic, abnormal chemical treatment: semaxanib Fig. 3 from Crucke et al., 2015
trunk blood circulation decreased occurrence, abnormal angiogenesis inhibitor: anti-angiogenic agent Fig. 4 from Venkateswaran et al., 2014
trunk intersegmental vessel branchiness, abnormal chemical treatment by environment: semaxanib Fig. S10 with image from Fu et al., 2017
trunk vasculature normal amount, normal chemical treatment: pharmaceutical Fig. 4 with image from Oehlers et al., 2011
trunk vasculature spatial pattern, normal chemical treatment: pharmaceutical Fig. 4 with image from Oehlers et al., 2011
trunk vasculature lacks parts or has fewer parts of type blood vessel endothelial cell filopodium, abnormal standard conditions Fig. 1 from Jiang et al., 2013
trunk vasculature physical object quality, normal chemical treatment: LY294002 Fig. 1 with image from Alvarez et al., 2009
trunk vasculature angiogenesis process quality, abnormal chemical treatment: pharmaceutical Fig. 5 from Lee et al., 2014
trunk vasculature angiogenesis process quality, abnormal chemical treatment: pharmaceutical Fig. 1 from Lee et al., 2014
trunk vasculature angiogenesis process quality, abnormal chemical treatment: pharmaceutical Fig. 1 from Lee et al., 2014
trunk vasculature blood circulation decreased occurrence, abnormal chemical treatment: blebbistatin Fig. 8 from Hultin et al., 2014
trunk vasculature blood vessel broken, abnormal chemical treatment by environment: ethanol Fig. 3 with image from Li et al., 2016
trunk vasculature blood vessel decreased amount, abnormal chemical treatment by environment: ethanol Fig. 2 with image from Li et al., 2016
trunk vasculature blood vessel decreased width, abnormal chemical treatment by environment: ethanol Fig. 2 with image from Li et al., 2016
trunk vasculature blood vessel morphology, abnormal chemical treatment by environment: ethanol Fig. 3 with image from Li et al., 2016
vasculature EGFP expression increased amount, abnormal cancer xenotransplantation Fig. 5 from Baltrunaite et al., 2017
vasculogenesis disrupted, abnormal chemical treatment: herbicide Fig. 5 with image from Kalén et al., 2009
vasculogenesis process quality, abnormal chemical treatment: thalidomide Fig. S18 from Ito et al., 2010
ventral aorta decreased diameter, abnormal chemical treatment by environment: N(gamma)-nitro-L-arginine methyl ester Fig. 3 with image from Sasagawa et al., 2016
ventral aorta diameter, ameliorated chemical treatment by environment: sodium nitroprusside, chemical treatment by environment: N(gamma)-nitro-L-arginine methyl ester Fig. 3 with image from Sasagawa et al., 2016
ventral aorta increased diameter, abnormal chemical treatment by environment: sodium nitroprusside Fig. 3 with image from Sasagawa et al., 2016
visual perception process quality, normal chemical treatment: LY294002 Fig. 8 with image from Alvarez et al., 2009
whole organism decreased length, abnormal chemical treatment by environment: benzo[a]pyrene, chemical treatment by environment: 17beta-estradiol Fig. 3 from Alharthy et al., 2017
whole organism decreased length, abnormal chemical treatment by environment: Fadrozole hydrochloride Fig. 3 from Alharthy et al., 2017
whole organism decreased length, abnormal chemical treatment by environment: 17beta-estradiol Fig. 3 from Alharthy et al., 2017
whole organism decreased length, abnormal chemical treatment by environment: benzo[a]pyrene Fig. 3 from Alharthy et al., 2017
whole organism decreased length, ameliorated chemical treatment by environment: Fadrozole hydrochloride, chemical treatment by environment: 17beta-estradiol Fig. 3 from Alharthy et al., 2017
whole organism decreased life span, abnormal chemical treatment by environment: Fadrozole hydrochloride Fig. 2 from Alharthy et al., 2017
whole organism decreased life span, abnormal chemical treatment by environment: benzo[a]pyrene, chemical treatment by environment: 17beta-estradiol Fig. 2 from Alharthy et al., 2017
whole organism decreased life span, exacerbated chemical treatment by environment: Fadrozole hydrochloride, chemical treatment by environment: 17beta-estradiol Fig. 2 from Alharthy et al., 2017
whole organism fli1b expression increased amount, abnormal cancer xenotransplantation Fig. 3 from Baltrunaite et al., 2017
whole organism kdrl expression increased amount, abnormal cancer xenotransplantation Fig. 3 from Baltrunaite et al., 2017
whole organism etv2 expression increased amount, abnormal cancer xenotransplantation Fig. 3 from Baltrunaite et al., 2017
whole organism estradiol decreased amount, abnormal chemical treatment by environment: benzo[a]pyrene Fig. 5 from Alharthy et al., 2017
whole organism estradiol decreased amount, abnormal chemical treatment by environment: Fadrozole hydrochloride Fig. 5 from Alharthy et al., 2017
yolk edematous, abnormal chemical treatment: SH-11037 Fig. 2 with image from Sulaiman et al., 2016
yolk edematous, abnormal chemical treatment by environment: benzo[a]pyrene Fig. 3 from Alharthy et al., 2017
yolk edematous, abnormal chemical treatment by environment: Fadrozole hydrochloride Fig. 3 from Alharthy et al., 2017
yolk edematous, ameliorated chemical treatment by environment: benzo[a]pyrene, chemical treatment by environment: 17beta-estradiol Fig. 3 from Alharthy et al., 2017
yolk edematous, ameliorated chemical treatment by environment: Fadrozole hydrochloride, chemical treatment by environment: 17beta-estradiol Fig. 3 from Alharthy et al., 2017

CITATIONS  (677)